Impact of COVID‐19 disease and vaccination on dermatological immune‐mediated inflammatory diseases atopic dermatitis, psoriasis, and vitiligo: a Target2B! substudy
The Journal of Dermatology · 2025
DOI: 10.1111/1346-8138.17664 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Nicoline F van Buchem-Post und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Netherlands Institute for Pigment Disorders, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam Inst…. Hauptthemen laut MEDLINE: COVID-19, Vitiligo, Psoriasis, Dermatitis, Atopic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw.
Abstract (Originalsprache)
During the COVID‐19 pandemic, the daily life of many patients with dermatological immune‐mediated inflammatory diseases (DIMIDs), such as atopic dermatitis (AD), psoriasis, and vitiligo, was impacted by social restrictions caused by (fear of) morbidity, mortality associated with COVID‐19, and vaccine hesitancy. This prospective observational, multicenter, multidisciplinary cohort study explored the impact of COVID‐19 disease and vaccination on DIMIDs, specifically AD, psoriasis, and vitiligo. Data from patients with DIMIDs were collected as part of the Target2B! study (between February 2021 and October 2022). We analyzed the differences in baseline characteristics, risk of developing COVID‐19, proportion of DIMIDs in patients reaching seroconversion upon vaccination per DIMID, and self‐reported increase in DIMID activity by multivariable logistic regression and sensitivity analyses. A total of 424 patients with DIMID were included. COVID‐19 disease commonly occurred in patients with vitiligo (51.1%), AD (42.0%), and psoriasis (34.3%) ( p = 0.038). COVID‐19 was not associated with the use of immunosuppressive therapy. Three patients (two with AD and one with vitiligo) were hospitalized due to COVID‐19. Nearly all patients with DIMIDs exhibited effective seroconversion after regular vaccination regimens (vitiligo 100%, psoriasis 97.9%, AD 96.5%). Increased DIMID activity after COVID‐19 (6.6%) or severe acute respiratory syndrome–related coronavirus (SARS‐CoV‐2) vaccination (12.26%) was reported in a minority of patients, with baseline progressive disease (disease activity 3 months preceding baseline survey) being the only associated risk factor (COVID‐19: odds ratio [OR], 4.27 [ p = 0.02]; vaccination OR, 3.45 [ p = 0.002]). In conclusion, no alarming signs were shown in this study regarding (severe) COVID‐19 in patients with AD, psoriasis, or vitiligo. Vaccination against COVID‐19 is advised in patients with DIMIDs. Moreover, patients with DIMIDs can safely continue their immunosuppressant therapy, since this does not increase the risk of COVID‐19, while vaccination‐induced humoral responses are adequate. In only a minority of patients, increased DIMID activity after COVID‐19 or SARS‐CoV‐2 vaccination occurred.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Netherlands Institute for Pigment Disorders, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam Institute for Immunology & Infectious Diseases, Amsterdam, Netherlands.
- National Heart Centre Singapore, Singapore, Singapore.
- Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, Netherlands.
- Department of Dermatology, Netherlands Institute for Pigment Disorders, Amsterdam University Medical Centers, VU University, Amsterdam Institute for Infection and Immunity, Rotterdam, Netherlands.
- Department of Dermatology, Erasmus University Rotterdam, Rotterdam, Netherlands.
ORCID-Profile: Nicoline F van Buchem-Post, Angela L Bosma
Förderung
- ZonMw
Zitieren
APA
van Buchem-Post, N. F., Ouwerkerk, W., Stalman, E. W., van Dam, K. P. J., Wieske, L., Bekkenk, M. W., Wolkerstorfer, A., Spuls, P., Musters, A. H., Bosma, A. L., Hijnen, D. J., Eftimov, F., Luiten, R. M., T2B! immunity against SARS‐CoV‐2 study group, van Kempen, Z. L. E., Stalman, E. W., Steenhuis, M., Kummer, L. Y. L., van Dam, K. P. J., …, & Brusse, E. (2025). Impact of COVID‐19 disease and vaccination on dermatological immune‐mediated inflammatory diseases atopic dermatitis, psoriasis, and vitiligo: a Target2B! substudy. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17664
Vancouver
van Buchem-Post NF, Ouwerkerk W, Stalman EW, van Dam KPJ, Wieske L, Bekkenk MW, et al. Impact of COVID‐19 disease and vaccination on dermatological immune‐mediated inflammatory diseases atopic dermatitis, psoriasis, and vitiligo: a Target2B! substudy. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17664
BibTeX
@article{vanBuchemPost2025,
author = {van Buchem-Post, Nicoline F and Ouwerkerk, Wouter and Stalman, Eileen W and van Dam, Koos P J and Wieske, Luuk and Bekkenk, Marcel W and Wolkerstorfer, Albert and Spuls, Phyllis and Musters, Annelie H and Bosma, Angela L and Hijnen, Dirk-Jan and Eftimov, Filip and Luiten, Rosalie M and T2B! immunity against SARS‐CoV‐2 study group, T2B! immunity against SARS‐CoV‐2 study group and van Kempen, Zoé L E and Stalman, Eileen W and Steenhuis, Maurice and Kummer, Laura Y L and van Dam, Koos P J and Ten Brinke, Anja and van Ham, S Marieke and Kuijpers, Taco and Rispens, Theo and Eftimov, Filip and Wieske, Luuk and Killestein, Joep and Kooi, A J Vd and Raaphorst, J and Zwinderman, A H Koos and Löwenberg, M and Volkers, A G and D'Haens, G R A M and Takkenberg, R B and Tas, S W and Hilhorst, M L and Vegting, Y and Bemelman, F J and Verstegen, N J M and Fernandez, L and Keijzer, S and Keijser, J B D and Cristianawati, O and Voskuyl, A E and Broens, B and Sanchez, A P and Nejentsev, S and Mirfazeli, E S and Wolbink, G J and Boekel, L and Rutgers, B A and de Leeuw, K and Horváth, B and Verschuuren, J J G M and Ruiter, A M and van Ouwerkerk, L and van der Woude, D and Allaart, Rcf and Teng, Yko and Busch, M H and Brusse, E},
title = {Impact of COVID‐19 disease and vaccination on dermatological immune‐mediated inflammatory diseases atopic dermatitis, psoriasis, and vitiligo: a Target2B! substudy},
journal = {The Journal of Dermatology},
year = {2025},
doi = {10.1111/1346-8138.17664}
}
EUVIMED